GLP-1 (Semaglutide)
FDA-approved across multiple indications, with one of the largest outcome-trial evidence bases in peptide therapeutics.
Evidence Score
Score Breakdown
Overview
Semaglutide is one of the most extensively studied peptides in metabolic medicine. FDA-approved for type 2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy injection and, since December 2025, the Wegovy pill), cardiovascular risk reduction (Wegovy 2024, Rybelsus 2025), kidney-disease risk reduction in type 2 diabetes with chronic kidney disease (Ozempic 2025), and noncirrhotic MASH with moderate-to-advanced fibrosis (Wegovy 2025, accelerated approval), it has amassed the largest clinical trial evidence base of any GLP-1 receptor agonist. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events.
Mechanism of Action
Semaglutide binds to the GLP-1 receptor with high affinity, triggering a cascade of metabolic effects: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction via hypothalamic signaling. The downstream gene expression changes are well-characterized across multiple tissue types.
Evidence Base
Multiple Phase III RCTs (STEP, SUSTAIN, PIONEER, SELECT, FLOW, ESSENCE programs) involving tens of thousands of participants. FDA-approved across multiple indications. Published in NEJM, Lancet, and JAMA with extensive post-market surveillance data.
Gene Pathway Detail
GLP-1 receptor activation triggers well-mapped gene expression cascades: CREB-mediated transcription in pancreatic β-cells, NF-κB pathway suppression reducing inflammatory cytokine expression (IL-6, TNF-α) and circulating CRP, SREBP1/FASN downregulation in hepatic lipogenesis, and IRS1/AKT activation in insulin signaling. The β-cell, hepatic and insulin-signaling effects occur in tissues; a whole-blood transcriptomic test reads the inflammatory side of this biology through circulating immune cells.
mRNA Monitoring Insight
Semaglutide has the best-characterized downstream biology of any compound on this list, which is why it scores highest here. Its anti-inflammatory effects are the part most relevant to a blood transcriptomic readout, because circulating immune cells carry that signal.
Safety Considerations
FDA-approved with extensive safety data. Most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea). Rare risks include pancreatitis and thyroid C-cell tumors (rodent signal). Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN 2.
FAQ
Why does semaglutide score so high?
Quick Facts
- Category
- Incretin Mimetic
- Score
- 94/100 (A)
- Gene Pathways
- 4 characterized
Compare Others
Track Your Immune Patterns on GLP-1 (Semaglutide) — Cohort Now Forming
See what your immune system is doing while you take GLP-1 (Semaglutide). Reserve your spot today to lock in founding pricing before the general public.